<DOC>
	<DOCNO>NCT00193583</DOCNO>
	<brief_summary>In phase I study characterize safety , tolerability , maximum tolerate dose dose-limiting toxicity weekly bolus topotecan administer combination two different dose schedule carboplatin . We also evaluate antitumor activity combination regimen .</brief_summary>
	<brief_title>Weekly Topotecan Combination With Carboplatin Two Different Schedules Refractory and/or Advanced Solid Tumors</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Topotecan + Carboplatin In order determine appropriate dose regimen progress future phase II trial , two different dose schedule topotecan carboplatin utilized ( ARM I ARM II ) . Patients accrued treatment arm simultaneously .</detailed_description>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Adult patient least 18 year old Advanced solid tumor refractory conventional therapy ECOG performance status must 0 1 Patients may receive 3 prior chemotherapy regimen Adequate bone marrow , liver kidney function Able understand nature study give write informed consent . You participate study follow apply : Active concurrent infection serious underlie medical condition Known HIV positivity Female patient pregnant lactate Received topotecan carboplatin Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>